Cytori Therapeutics, Inc.

Company Details:

Company Symbol: CYTX
Sector: Healthcare & Medical Devices
Company Rating:

Related Research

  • 03/20/17 Morning Note B. Riley AM Note: ARC (resuming coverage), CYTX, GSM, LOV, RTEC; Exhibitors (AMC, CNK, IMAX, MCS, RDI, RGC), The Weiser Consumer (EL, IPAR, NTRI, PG, PRGO)
  • 03/20/17 Update CYTX ($1.65, Buy; $6.75 PT): 4Q16 Preview: Q4 Estimates Seem Reasonable, Also Expecting Additional Color on Azaya Acquisition & Initial 2017 Outlook; Maintaining Buy Rating & $6.75 PT
  • 02/16/17 Update CYTX ($1.99, Buy; $6.75 PT): CYTX Diversifies its Business Through the Acquisition of Azaya Therapeutics, Inc.; Increasing PT to $6.75 from $5.75
  • 02/16/17 Morning Note B. Riley AM Note: ADI, AMAT, CFMS, CYTX, GDDY, GRPN, MAMS, MCHP, SONS, TIVO
  • 01/20/17 Morning Note B. Riley AM Note: CYTX, IIVI, SWKS; Internet (GOOGL, YHOO)
  • 12/29/16 Morning Note B. Riley AM Note: CYTX
  • 12/16/16 Update CYTX (B. Riley & Co. Initiation: $1.44, Buy; $5.75 PT): Strengthening its “Grip” on Adipose Derived Regenerative Cell Therapies; Initiating Coverage with a Buy & $5.75 Price Target
  • 12/16/16 Morning Note B. Riley AM Note: CAMP, CYTX (initiation), EXAR, FINL, IDCC, JBL, NKE, PCOM